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Gene therapy for renal anemia in mice with polycystic kidney Erythropoietin (EPO) synthesized in renal peritubular
using an adenovirus vector encoding the human erythropoietin cells in response to hypoxia regulates erythropoiesis in
gene. the bone marrow [1–3]. The activity of EPO has been
Background. Recombinant human erythropoietin (rHuEPO)
reported to depend on the number of sialic acid residuesis primarily used for patients with anemia associated with end-
[4, 5]. Intravenous or subcutaneous injection of recombi-stage renal disease. We evaluated the efficacy of EPO gene
nant human EPO (rHuEPO) once to three times weeklytherapy using adenovirus vector for chronic renal failure mice
expressing severe renal anemia. results in an improved quality of life for patients with
Methods. Recombinant HuEPO gene transfer to mesothe- end-stage renal disease [6–8]. As an alternative persistent
lial cells was performed in vitro and in vivo. Recombinant EPO therapy, implantation of cells genetically modified
replication-deficient adenoviruses containing rHuEPO cDNA to secrete rHuEPO has been applied in nephrectomized(AdCMVEPO), E. coli lacZ gene (AdCMVlacZ), or an nonex-
nude mice and other experimental animals [9, 10]. Repli-ogenous gene (AdNull as control vector) driven by the cyto-
cation-deficient adenovirus vectors have also been usedmegalovirus promotor/enhancer were constructed. The oligo-
saccharides associated with the rHuEPO from AdCMVEPO- for in vivo transfer of rHuEPO genes into the peritoneal
treated mesothelial cells were analyzed. For in vivo study, the cells of normal rats or into the muscle cells of severe
DBA/2FG-pcy mouse, a model for human autosomal recessive combined immunodeficient mice [11–13].
polycystic kidney disease resulting in chronic renal failure with For gene therapy studies, appropriate experimentalprogressive anemia, was used.
animal models play a key role in the evaluation of physio-Results. The sialylated oligosaccharides associated with the
logical effects of transgene expression [14]. In this study,rHuEPO produced in AdCMVEPO-treated mesothelial cells
occupied 78 6 0.7% of the total oligosaccharide pool. A we used DBA/2FG-pcy mice with chronic renal failure
single intraperitoneal administration of AdCMVEPO induced and severe anemia for the assessment of EPO gene ther-
rHuEPO synthesis in the peritoneal cells and a marked increase apy. The DBA/2FG-pcy mice have been established as a
in erythrocyte production. The maximal increase in hematocrit
good model for polycystic kidney disease. These animals(43 6 4%) was observed on day 28, and it remained elevated
develop progressive anemia caused by chronic renal fail-for 40 days.
ure [15, 16]. We have previously reported that stim-Conclusion. These results indicate that intraperitoneal ad-
ministration of AdCMVEPO improves renal anemia in mice ulation of erythropoiesis by intraperitoneal adminis-
with chronic renal failure and that the mesothelial cell is an tration of a replication-deficient adenovirus bearing the
appropriate target cell for gene transfer. rHuEPO gene is stronger than that by subcutaneous
administration in experimental animals with intact renal
function. In this study, we assessed the bioactivity and
Key words: recombinant human erythropoietin, mesothelial cell,
excretion of transgene-encoded protein in mesothelialDBA/2FG-pcy mouse, gene therapy, end-stage renal disease, polycystic
kidney disease. cells and their appropriateness as target for in vivo gene
transfer in uremic animals. Our results demonstrated
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METHODS Analysis of oligosaccharides associated with human
erythropoietin produced by AdCMVEPO-treatedAdCMV-EPO construction
4/4RM-4 cells
A recombinant replication-deficient adenovirus bear-
A 400 ml supernatant of the cultured medium ofing the rHuEPO cDNA (AdCMVEPO; kindly provided
AdCMVEPO-treated 4/4RM-4 cells was collected andby Genetics Institute Co., Cambridge, MA, USA), the E.
concentrated with YM10 (Amicon, Beverly, MA, USA).coli lacZ gene (AdCMVlacZ), and nonexogenous gene
An approximately 20 mg glycoprotein sample was sub-(AdNull as control vector) driven by the cytomegalovi-
jected to rigorous preparation. After exhaustive mi-rus promotor/enhancer was constructed as described pre-
croflow dialysis against 0.1% trifluoroacetic acid, the ly-viously [12]. Briefly, these three vectors were propagated
ophilized sample was eluted on GlycoPrepe 1000 (Ox-in the human embryonic kidney cell line 293 (ATCC
ford GlycoSystems, London, UK), and the released oli-CRL-1573; ATCC, Rockville, MD, USA), purified by
gosaccharides were recovered. The sample was fluores-cesium chloride density gradient centrifugation, dia-
cently labeled by reductive amination with 2-amino-lyzed, and stored in multiple aliquots at 2808C. Viral
benzamide, applied to a Whatman 3 MM disc (Whatmantiters were determined by plaque assay on 293 cells.
International, Maidstone, UK), and subjected to chro-
matographic purification. The 2-aminobenzamide–In vitro adenovirus-mediated gene transfer
labeled oligosaccharide pool was subjected to high-per-A rat mesothelial cell line, 4/4RM-4 (ATCC CRL-
formance liquid chromatography (HPLC) on a Glyco-216) and a Chinese hamster ovary (CHO) cell line
SepC column (Oxford GlycoSystems) using acetonitrile(ATCC CRL-1793) were prepared to evaluate the suit-
and ammonium acetate as the eluent. To determine theability of AdCMVEPO for synthesis of rHuEPO in vitro.
characteristics of the acidic substituents of the oligosac-AdCMVEPO, AdNull (5 3 107 pfu) or phosphate-buf-
charides, an aliquot of the total pool of fluorescentlyfered saline (PBS) was added to mesothelial cells (1 3
labeled oligosaccharides was incubated with neuramini-106 cells) in serum-free Ham’s F12K medium (Sigma, St.
dase and then subjected to GlycoSepC chromatography.Louis, MO, USA) or to CHO cells (1 3 106 cells) in
serum-free Ham’s F12K medium or to CHO cells
In vivo adenovirus-mediated gene transfer(1 3 106 cells) in serum-free a-modified Eagle’s medium
To evaluate the adenovirus-mediated in vivo gene(MEM; GIBCO-BRL, Gaithersburg, MD, USA). The
transfer, AdCMVlacZ, AdNull (108 pfu/animal), or sa-secretion of rHuEPO in AdCMVEPO-infected mesothe-
line was administered to the peritoneal cavity of 20- tolial cells and in CHO cells was determined by radioimmu-
22-week-old male or female DBA/2FG-pcy mice (N 5noassay using rabbit antibody against epoetin a (Recom-
5 in each group) with uremia (BUN more than 60 mg/dl)bigen EPO kit; Japan DPC, Tokyo, Japan) [17].
and severe anemia (Hct less than 25%). These mice wereTo evaluate the glycosylation of EPO, AdCMVEPO-
provided by the Laboratory Animal Center (Instituteinfected mesothelial cells were treated with or without
for Comprehensive Medical Science, Fujita Health Uni-tunicamycin (2.5 mg/ml; Sigma), an inhibitor of glycosyla-
versity, Toyoake, Japan). Twenty-four hours after thetion. Forty-eight hours after inoculation, the supernatant
administration, the mice were anesthetized by diethyl-was collected. The molecular weight of rHuEPO se-
ether inhalation (Wako Chemicals, Tokyo, Japan) andcreted from AdCMVEPO-infected mesothelial cells was
killed. The peritoneal tissues were fixed in 5% formalde-determined by sodium dodecyl sulfate-polyacrylamide
hyde and 0.5% glutaraldehyde/PBS at 48C for 30 min-gel electrophoresis (SDS-PAGE) and immunoblot anal-
utes. The tissues were stained with 5 mm K4Fe(CN)6,ysis. Three units of recombinant rHuEPO produced by
5 mm K3Fe(CN)6 (Sigma), 2 mm MgCl2, and 200 mg/mlmodified CHO cells (EPOCHt; Chugai Pharmaceutical
X-Gal reagent (5-bromo-4-chloro-3-indolyl-b-D-galac-Co., Tokyo, Japan) as a positive control and the those
topyranoside; Boehringer Mannheim, Mannheim, Ger-secreted from AdCMVEPO-infected mesothelial cells
many) for one hour at 378C as reported previously [18].were electrophoresed in 12.5% sodium dodecyl sulfate
The tissues were identified as positive for b-galactosidasepolyacrylamide gel. Proteins fractionated by electropho-
activity by the blue stain of the X-Gal reaction [18].resis were transferred onto polyvinyldene difluoride
To detect rHuEPO mRNA transcripts from peritoneal(PVDF) membranes (Millipore, Tokyo, Japan). Immu-
mesothelial cells, the mice were killed 24 hours afternoblot analysis was performed using 1 mg/ml mouse anti-
intraperitoneal administration of AdCMVEPO, AdNullrHuEPO antibody (Genzyme, Cambridge, MA, USA).
Antibodies bound to the proteins on the membrane were (108 pfu/animal), or saline. The peritoneal cavity was
washed with PBS, and 4 m of guanidine thiocyanatedetected with horseradish peroxidase-conjugated goat
antimouse IgG (1:1000; Zymed Inc., San Francisco, CA, (Fluka, Buchs, Switzerland) were instilled directly into
the peritoneal cavity. After one minute, the guanidineUSA) and were visualized by an ECL Western blot anal-
ysis kit (Amersham, Buckinghamshire, UK). thiocyanate-containing peritoneal cell lysate was col-
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lected, and total RNA was extracted by the phenol/
chloroform purification method as described previously
[19]. Recombinant human EPO mRNA in the perito-
neum was analyzed by Northern blotting using 10 mg of
total RNA hybridized with a random-primed 32P-labeled
rHuEPO cDNA. For control, the same membrane was
subsequently hybridized with a mouse glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) cDNA probe la-
beled in the same fashion.
To assess the effects of intraperitoneal administration
of AdCMVEPO on red blood cell production, DBA/
2FG-pcy mice were killed on days 0, 21, 28, and 40. Fifty
microliters of blood were collected on each day, and the
hematocrit was measured.
Serum rHuEPO levels were measured by radioimmu-
noassay using the same antibody as in the in vitro study.
Blood cells were prepared to count erythroid precursors
in bone marrow from the femur and to count reticulo-
cytes in peripheral blood. For each mouse, bone marrow
samples stained with Wright-Giemsa and peripheral
blood samples stained with 0.5% methylene blue were
prepared in duplicate. Bone marrow and peripheral
blood smears were examined by light microscopy to de-
termine the proportion of erythroid precursors among
the nucleated bone marrow cells (a minimum of 500 cells Fig. 1. Western blot analyzes of rHuEPO in the supernatant from
counted per animal) and the proportion of reticulocytes infected mesothelial cells with AdCMVEPO. Lane 1, the supernatant
from mesothelial cells exposed to phosphate-buffered saline as control.among red blood cells (a minimum of 500 cells per ani-
Lane 2, the supernatant from mesothelial cells infected with the controlmal). Each sample was prepared in duplicate. vector AdNull. Lane 3, the supernatant from mesothelial cells infected
with AdCMVEPO. Lane 4, the supernatant from mesothelial cells in-
Statistical analysis fected with AdCMVEPO with the addition of tunicamycin (2.5 mg/ml).
Lane 5, recombinant human EPO produced by modified CHO cellsResults are expressed as mean 6 sd. Statistical analysis (EPOCHt).
was performed using analysis of variance, with P , 0.05
accepted as statistically significant. For hematocrit analy-
sis, three groups were cross compared using Bonferroni’s
method. 4/4RM-4 cells treated with PBS or with AdNull as the
control vector did not show any bands specific for
rHuEPO (Fig. 1).
RESULTS
The relative molar content of neutral and acidic oligo-
In vitro adenovirus-mediated gene transfer saccharides in the total pool was determined by integra-
tion of chromatographic peaks (data not shown). AnionRecombinant human EPO (54,300 6 8100 mU/ml)
was synthesized in 4/4RM-4 mesothelial cells (1 3 106) exchange chromatography showed that oligosaccharides
associated with rHuEPO produced by AdCMVEPO-48 hours after the inoculation with AdCMVEPO (5 3
107 pfu), which is significantly higher than 5440 6 420 treated 4/4RM-4 cells consisted of 22 6 1.0% of neutral
components and 78 6 0.7% of acidic components. AftermU/ml rHuEPO synthesized in CHO cells (P , 0.001).
In contrast, the 4/4RM-4 cells treated with PBS or with incubation with neuraminidase, no acidic oligosaccha-
rides were detected by chromatography (data notAdNull produced little rHuEPO (,10.0 mU/ml).
Western blot analyses of rHuEPO in the supernatant shown).
of 4/4RM-4 cells infected with AdCMVEPO showed the
In vivo adenovirus-mediated gene transferpresence of 30.3 kDa rHuEPO, which was the same
molecular weight as recombinant HuEPO produced in AdCMVlacZ, AdNull as the control vector, or PBS
as control was administered to the peritoneal cavity ofthe modified CHO cells (EPOCHt). In the presence of
2.5 mg/ml tunicamycin, AdCMVEPO-infected 4/4RM-4 DBA/2FG-pcy mice (Fig. 2A, a–c). Twenty-four hours
after the administration of AdCMVlacZ, blue colorationcells synthesized rHuEPO with two different molecular
weights: approximately 21 and 22 kDa. These smaller by X-gal staining was observed only in the visceral and
parietal mesothelial cells, as reported previously [20].bands show EPO with insufficient glycosylation. The
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Fig. 2. In vivo gene transfer to mouse peritoneal mesothelium. (A) In vivo transfer of the E. coli lacZ gene to DAB/2FG-pcy mouse peritoneum.
Two days after AdCMVEPO was administered intraperitoneally, the peritoneum was examined to assess the presence of the lacZ product
(b-galactosidase) by using X-Gal stain (Blue staining). (a) Peritoneal section covering the surface of the abdominal muscle from a mouse infected
with AdCMVlacZ demonstrates b-galactosidase expression in mesothelial cells. (b) Peritoneal section from a mouse infected with the control
vector AdNull. (c) Peritoneal section from a mouse treated with phosphate-buffered saline (3400). (B) Hematoxylin-eosin staining of peritoneal
section from a mouse infected with the control vector AdNull (3400). No toxic changes due to administration of adenovirus and no inflammatorical
changes such as cell infiltration or sclerotic changes were observed in the peritoneum.
No other cells accessible to the virus in the peritoneum peritoneal administration of AdCMVEPO resulted in
mean serum rHuEPO levels of 2559 mU/ml for 40 days,showed lacZ gene expression. The administration of
AdNull or PBS resulted in an absence of blue coloration with a maximum level of 14,730 6 930 mU/ml on day
10 after administration. Serum rHuEPO levels remainedby X-gal staining. No inflammatorical changes, including
cell infiltration and fibrotic changes, and no toxic changes high with a mean level of 154 mU/ml on day 40. However,
in control mice treated with PBS or AdNull, serumcaused by adenoviral administration were observed in
the histology of the peritoneum obtained from AdNull- rHuEPO levels were less than 10.0 mU/ml.
Erythroid precursors within the bone marrow of theor AdCMVEPO-inoculated mice (Fig. 2B).
Northern blot analysis using rHuEPO cDNA showed untreated mice were 13 6 1% of all nucleated hemato-
poietic cells, whereas they were reached 24 6 1% onrHuEPO cDNA transcripts in the peritoneum of mice
treated with AdCMVEPO (Fig. 3, lane 3). In contrast, day 4 after treatment with AdCMVEPO (P , 0.001)
and decreased thereafter. Reticulocytes in untreatedno rHuEPO cDNA transcripts were detected in the peri-
toneum of uninfected mice or AdNull-infected mice (Fig. mice were 1.5 6 0.2% of the total circulating red blood
cells. However, reticulocytes in mice treated with3, lanes 1 and 2). Mouse glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA expression was simi- AdCMVEPO reached 20 6 3.4% on day 21 (P , 0.001)
and decreased to 5% by day 40. In control mice treatedlar in each sample (Fig. 3, lanes 4–6).
Figure 4 shows serum rHuEPO levels measured on with PBS or AdNull, no significant changes were noticed
in the number of reticulocytes (Fig. 5). The hematocritdays 0, 10, 21, 28, and 40 after intraperitoneal administra-
tion of 108 pfu AdCMVEPO, AdNull, or PBS. The intra- was also increased significantly in mice treated with
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Fig. 4. Serum human erythropoietin (rHuEPO) levels after a single
intraperitoneal administration of AdCMVEPO (108 pfu), AdNull (108
pfu), or PBS. Each symbol represents the mean value from two separate
readings for each mouse. Shown are data for AdCMVEPO-infected
mice (d), mice treated with AdNull as the control vector (s), and mice
treated with PBS as control (n). Serum rHuEPO levels were measured
by radioimmunoassay. Horizontal lines indicate the mean serum EPO
level for each group. Note the high level of rHuEPO in the serum of
AdCMVEPO-infected mice.
twofold by the intraperitoneal administration of the ade-
novirus vector containing rHuEPO cDNA (Fig. 6).
DISCUSSION
The bioactivity and the regulation of the transgene-
encoded protein were not examined in our previous
study [12, 20]. Glycosylation depends on host cells and
the peptide structure of glycoprotein [21]. This study
showed that mesothelial cells modified by AdCMVEPO
synthesize bioactive rHuEPO with nearly the same gly-
cosylation pattern as EPOCHt. In our in vitro study, the
mesothelial cells transfected with AdCMVEPO secreted
Fig. 3. Human erythropoietin (rHuEPO) cDNA expression in perito- 10-fold more glycosylated rHuEPO than the modified
neal tissue following intraperitoneal administration of AdCMVEPO to CHO cells transfected with AdCMVEPO.mice. Shown are Northern blot analyses of peritoneal cells two days
Tunicamycin, an inhibitor of N-linked glycosylation,after infection. RNA extracted from the mouse peritoneum (10 mg/
lane) was hybridized with a rHuEPO cDNA probe (lanes 1–3) or a rat was previously reported to abolish the secretion of EPO
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe in the human hepatoblastoma cell line [22]. In this study,(lanes 4–6). Lane 1, peritoneum from a mouse treated with phosphate-
AdCMVEPO-infected 4/4RM-4 cells with tunicamycinbuffered saline as control. Lane 2, peritoneum from a mouse after
intraperitoneal administration of the control vector AdNull. Lane 3, synthesized rHuEPO with two different smaller molecu-
peritoneum from a mouse after intraperitoneal administration of lar weights. This suggests that AdCMVEPO-infectedAdCMVEPO. Lanes 4–6 are identical with lanes 1–3, except that RNA
mesothelial cells synthesize glycosylated rHuEPO. Thewas hybridized with a rat GAPDH probe. Note the EPO-specific band
in lane 3. terminal sialic acid residues in the carbohydrate chains
are essential for the bioactivity of rHuEPO in vivo [4, 5].
In this study, all acidic components were sialylated, and
the sialylated saccharides made up 78% of the total oligo-AdCMVEPO on days 28 and 40 compared with that in
saccharides of rHuEPO produced by AdCMVEPO-control mice treated with PBS or AdNull. Before the
treated mesothelial cells.administration of AdCMVEPO, the mean hematocrit
The advantage of using DBA/2FG-pcy mice in EPOlevel was 24 6 3% at 20 weeks. Following a single admin-
gene therapy for renal anemia is that they provide aistration of AdCMVEPO, the average hematocrit
good model of polycystic kidney disease with eventualreached 43 6 4% on day 28 and remained elevated on
day 40 (42 6 5%). Thus, the hematocrit levels increased severe anemia [16, 23, 24]. The anemia in DBA/2FG-
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Fig. 6. The increase in hematocrit from the baseline for each mouse
administered AdCMVEPO, AdNull, or phosphate-buffered saline
(PBS) intraperitoneally. Data are shown after the intraperitoneal ad-
ministration of AdCMVEPO (d), AdNull (s), or PBS (n), and are
means 6 se. *P , 0.05; **P , 0.01.
difficulties, immunosuppressive agents were used or E1/
Fig. 5. Effects of intraperitoneal administration of AdCMVEPO on E4-deleted adenovirus vectors and E3-expressed adeno-
murine blood reticulocytes. AdCMVEPO, AdNull, or phosphate-buf- virus vectors were constructed [27, 28]. The construction
fered saline was administered to mice as described in the Methods
of a new generation of adenovirus vector with lowersection. Data are shown for intraperitoneal administration of
AdCMVEPO (d), AdNull (s) or saline (n). immunogenicity is now in progress in our laboratory.
There were some nonresponding animals in our study.
Some possible explanations include a different host im-
munologic response to the foreign transgene, instability
pcy mice is thought to be a result of insufficient EPO of the efficiency of adenovirus-infection to peritoneum
synthesis, an increase in osmotic fragility of erythrocytes, in vivo.
and a decreased response of erythroid progenitor cells There are two major advantages in using adenovirus-
to EPO in the long-term uremic milieu [16]. In this study, mediated in vivo gene transfer. The transfer of exoge-
DBA/2FG-pcy mice receiving a single intraperitoneal nous genes is simple: a single injection of replication-
administration of AdCMVEPO showed a persistent in- deficient adenovirus vector. No effort is required to con-
crease in serum rHuEPO from the basal levels for at trol overexpression of the transgene in terms of transient
least 40 days. In our previous study using AdMLP-Epo, expression. An ex vivo gene therapy approach is rather
however, serum rHuEPO levels decreased to basal levels laborious because it requires the isolation, growth, and
within 14 days. The reason for this discrepancy remains transfection of primary human myoblasts from each pa-
unknown. It may be due to the different target animals tient to be treated.
or to the different promotors for the gene transfer. Our results demonstrate that a single intraperitoneal
The relatively short-term expression of a transgene administration of rHuEPO cDNA with an adenovirus
using adenovirus vectors has been postulated to be due vector can produce a physiologically effective expression
to a cellular immunity against cells bearing the transgene of recombinant human erythropoietin that promotes
[25] or to immune responses to foreign transgene-en- erythropoiesis and can ameliorate progressive renal ane-
coded protein [26]. These responses, together with the mia successfully in DBA/2FG-pcy mice with chronic re-
epichromosomal position of the transgene, limit the du- nal failure. This study also suggests that the mesothelial
ration of expression ranging weeks to month. Thus, ade- cell may be an appropriate target cell for gene transfer.
novirus vectors need to be readministered periodically to
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